Vivesto AB (VIVE) - Net Assets
Based on the latest financial reports, Vivesto AB (VIVE) has net assets worth Skr133.57 Million SEK (≈ $14.37 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr150.01 Million ≈ $16.14 Million USD) and total liabilities (Skr16.44 Million ≈ $1.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Vivesto AB (VIVE) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr133.57 Million |
| % of Total Assets | 89.04% |
| Annual Growth Rate | 8.43% |
| 5-Year Change | -76.95% |
| 10-Year Change | -51.44% |
| Growth Volatility | 52.19 |
Vivesto AB - Net Assets Trend (2004–2024)
This chart illustrates how Vivesto AB's net assets have evolved over time, based on quarterly financial data. Also explore Vivesto AB balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Vivesto AB (2004–2024)
The table below shows the annual net assets of Vivesto AB from 2004 to 2024. For live valuation and market cap data, see Vivesto AB market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr158.33 Million ≈ $17.04 Million |
-19.96% |
| 2023-12-31 | Skr197.80 Million ≈ $21.29 Million |
-39.22% |
| 2022-12-31 | Skr325.42 Million ≈ $35.02 Million |
-40.80% |
| 2021-12-31 | Skr549.71 Million ≈ $59.16 Million |
-19.95% |
| 2020-12-31 | Skr686.74 Million ≈ $73.90 Million |
-16.19% |
| 2019-12-31 | Skr819.39 Million ≈ $88.18 Million |
+93.23% |
| 2018-12-31 | Skr424.05 Million ≈ $45.63 Million |
+22.90% |
| 2017-12-31 | Skr345.04 Million ≈ $37.13 Million |
+14.87% |
| 2016-12-31 | Skr300.37 Million ≈ $32.32 Million |
-7.88% |
| 2015-12-31 | Skr326.05 Million ≈ $35.09 Million |
-13.22% |
| 2014-12-31 | Skr375.71 Million ≈ $40.43 Million |
+33.27% |
| 2013-12-31 | Skr281.91 Million ≈ $30.34 Million |
-11.67% |
| 2012-12-31 | Skr319.15 Million ≈ $34.35 Million |
+16.70% |
| 2011-12-31 | Skr273.47 Million ≈ $29.43 Million |
-7.04% |
| 2010-12-31 | Skr294.17 Million ≈ $31.66 Million |
+107.45% |
| 2009-12-31 | Skr141.80 Million ≈ $15.26 Million |
+131.68% |
| 2008-12-31 | Skr61.21 Million ≈ $6.59 Million |
-5.56% |
| 2007-12-31 | Skr64.81 Million ≈ $6.97 Million |
-41.24% |
| 2006-12-31 | Skr110.30 Million ≈ $11.87 Million |
+87.27% |
| 2005-12-31 | Skr58.90 Million ≈ $6.34 Million |
+87.58% |
| 2004-12-31 | Skr31.40 Million ≈ $3.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Vivesto AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8258.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr53.80 Million | 33.98% |
| Other Components | Skr2.03 Billion | 1284.84% |
| Total Equity | Skr158.33 Million | 100.00% |
Vivesto AB Competitors by Market Cap
The table below lists competitors of Vivesto AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bang Overseas Limited
NSE:BANG
|
$5.59 Million |
|
Linkage Global Inc Ordinary Shares
NASDAQ:LGCB
|
$5.59 Million |
|
Hydrofarm Holdings Group Inc
NASDAQ:HYFM
|
$5.59 Million |
|
PMPG Polskie Media S.A.
WAR:PGM
|
$5.59 Million |
|
Aptorum Group Ltd Class A
NASDAQ:APM
|
$5.59 Million |
|
JPMorgan Indian Inv Trust
LSE:JII
|
$5.58 Million |
|
Masivo Silver Corp
V:MASS
|
$5.58 Million |
|
Destiny Media Technologies Inc
V:DSY
|
$5.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vivesto AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 197,799,000 to 158,328,000, a change of -39,471,000 (-20.0%).
- Net loss of 39,754,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-39.75 Million | -25.11% |
| Other Changes | Skr283.00K | +0.18% |
| Total Change | Skr- | -19.96% |
Book Value vs Market Value Analysis
This analysis compares Vivesto AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.14x to 0.29x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | Skr0.60 | Skr0.08 | x |
| 2005-12-31 | Skr1.13 | Skr0.08 | x |
| 2006-12-31 | Skr2.09 | Skr0.08 | x |
| 2007-12-31 | Skr1.18 | Skr0.08 | x |
| 2008-12-31 | Skr1.08 | Skr0.08 | x |
| 2009-12-31 | Skr2.36 | Skr0.08 | x |
| 2010-12-31 | Skr4.06 | Skr0.08 | x |
| 2011-12-31 | Skr3.05 | Skr0.08 | x |
| 2012-12-31 | Skr2.88 | Skr0.08 | x |
| 2013-12-31 | Skr2.13 | Skr0.08 | x |
| 2014-12-31 | Skr2.56 | Skr0.08 | x |
| 2015-12-31 | Skr2.11 | Skr0.08 | x |
| 2016-12-31 | Skr1.66 | Skr0.08 | x |
| 2017-12-31 | Skr1.37 | Skr0.08 | x |
| 2018-12-31 | Skr1.44 | Skr0.08 | x |
| 2019-12-31 | Skr2.06 | Skr0.08 | x |
| 2020-12-31 | Skr-2.63 | Skr0.08 | x |
| 2021-12-31 | Skr1.23 | Skr0.08 | x |
| 2022-12-31 | Skr0.66 | Skr0.08 | x |
| 2023-12-31 | Skr0.32 | Skr0.08 | x |
| 2024-12-31 | Skr0.29 | Skr0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vivesto AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-25.11%) is above the historical average (-27.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 7.98% | 22776190.91% | 0.00x | 1.15x | Skr-634.53K |
| 2005 | -12.41% | -856.40% | 0.01x | 1.08x | Skr-13.20 Million |
| 2006 | -8.86% | -43.58% | 0.19x | 1.10x | Skr-20.78 Million |
| 2007 | -7.83% | -7.12% | 0.81x | 1.35x | Skr-11.54 Million |
| 2008 | -11.63% | -8.95% | 0.82x | 1.59x | Skr-13.22 Million |
| 2009 | -12.03% | -55.48% | 0.17x | 1.27x | Skr-31.23 Million |
| 2010 | -22.42% | -62226.42% | 0.00x | 1.09x | Skr-95.38 Million |
| 2011 | -24.01% | -7370.37% | 0.00x | 1.28x | Skr-93.02 Million |
| 2012 | -22.68% | 0.00% | 0.00x | 1.39x | Skr-104.30 Million |
| 2013 | -37.29% | -175186.67% | 0.00x | 1.66x | Skr-133.30 Million |
| 2014 | -31.27% | -5676.18% | 0.00x | 1.37x | Skr-155.07 Million |
| 2015 | -43.41% | -2220.92% | 0.01x | 1.58x | Skr-174.14 Million |
| 2016 | -53.35% | -93164.53% | 0.00x | 1.74x | Skr-190.28 Million |
| 2017 | -34.20% | -3723.79% | 0.01x | 1.65x | Skr-152.51 Million |
| 2018 | -40.33% | -8637.37% | 0.00x | 1.52x | Skr-213.42 Million |
| 2019 | -1.29% | -5.22% | 0.20x | 1.23x | Skr-92.47 Million |
| 2020 | 0.00% | -5.22% | 0.23x | 0.00x | Skr111.85 Million |
| 2021 | -25.28% | -530.49% | 0.04x | 1.08x | Skr-193.92 Million |
| 2022 | -112.79% | -36160.59% | 0.00x | 1.09x | Skr-399.57 Million |
| 2023 | -65.09% | 0.00% | 0.00x | 1.12x | Skr-148.52 Million |
| 2024 | -25.11% | 0.00% | 0.00x | 1.09x | Skr-55.59 Million |
Industry Comparison
This section compares Vivesto AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $572,993,345
- Average return on equity (ROE) among peers: -71.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vivesto AB (VIVE) | Skr133.57 Million | 7.98% | 0.12x | $5.59 Million |
| BioGaia AB (publ) (BIOG-B) | $463.89 Million | 38.92% | 0.24x | $1.26 Billion |
| Enzymatica publ AB (ENZY) | $-901.48K | 0.00% | 0.00x | $66.35 Million |
| Enorama Pharma AB (ERMA) | $7.18 Million | -344.33% | 4.93x | $2.25 Million |
| Gabather AB (publ) (GABA) | $3.44 Million | -248.55% | 0.96x | $1.04 Million |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $23.19 Million |
| Moberg Pharma AB (publ) (MOB) | $201.49 Million | -5.64% | 0.35x | $58.17 Million |
| Nanexa AB (NANEXA) | $16.96 Million | -37.43% | 0.21x | $60.08 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $49.38 Million | -39.35% | 0.48x | $4.48 Million |
| Orexo AB (ORX) | $25.52 Million | -81.53% | 0.30x | $70.45 Million |
| Swedish Orphan Biovitrum AB (publ) (SOBI) | $4.96 Billion | 0.36% | 0.35x | $15.91 Billion |
About Vivesto AB
Vivesto AB develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also offers Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixi… Read more